NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Wall Street was moving higher still shortly after the open, on the back of slightly better-than-expected readings for US ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

Government, IoT, and Cybersecurity sectors, announced today that it has entered into securities purchase agreements with certain institutional investors to purchase 545,454 ordinary ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a ...